Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas

李有君; 朱诚; 张光霁; 孔宪涛; 张橹榕

Your Location：

Home >

Browse articles >

Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas

Updated：2026-03-12

- Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas
- Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas
- 解放军医学杂志（英文版） 1992年第2期页码：173-177
- Affiliations：
  
  1. Department of Neurosurgery and Clinical Immunology Center Changzheng Hospital
  2. Second Military Medical University
  3. ,Shanghai,200433
- Author bio：
- Funds：
- DOI：
  中图分类号：
- 纸质出版：1992
- Accepted：
Scan QR Code
Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas[J]. 解放军医学杂志（英文版）, 1992,(2):173-177.

[1]李有君,朱诚,张光霁,孔宪涛,张橹榕.Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas[J].Journal of Medical Colleges of PLA,1992(02):173-177+182.
Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas[J]. 解放军医学杂志（英文版）, 1992,(2):173-177. DOI：

[1]李有君,朱诚,张光霁,孔宪涛,张橹榕.Biocharacterizations of T lymphocytes infiltrating human primary brain gliomas[J].Journal of Medical Colleges of PLA,1992(02):173-177+182. DOI：

摘要

Abstract

正

Glioma-infiltrating lymphocytes（GIL）were isolated from 9 surgical biopsy specimens of pri-mary brain gliomas using mechanical and enzymatic digestion and discontinuous density gradientcentfifugation.Durng culture in the presence of interleukin-2（IL-2）for a period of four weeks

GIL were expanded by 48.4-fold on the avea-age

even up to 118-fold.GIL activated by IL-2 hadspcific cytolytic activity against autologous glioma cells.Analysis of cell surface phenotypes offreshly isolated GIL showed that CD3

cells were 71.0±11.9％

CD4

cells 34.2±6.1％ and CD8

cells 37.0±7.6％.Ability of IL-2-activated GIL to secrete γ-interferon（γ-IFN）was significantlyhigher than that of freshly isolated GIL and autologous peripheral blood lymphocytes（PBL）.Theresults suggest that GIL have many advantages as an adoptive immunotherapy for patients withgliomas and as a new type of antitumor immune effector.

关键词

Keywords

references

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据